Journal of neurosurgery · 2000 · 116 citations · 11 references
MedicineNeurosurgeryPharmacologyCerebrovascular NeurosurgeryCerebrovascular SurgeryNeuropharmacologyCerebrovascular DiseaseCerebrovascular PhysiologyNeuroprotectionStrokeSubarachnoid HemorrhageSubarachnoid Hemorrhage ManagementAneurysmal Subarachnoid Hemorrhage VasospasmCerebral Ischemia PharmacotherapyCerebral Vasospasm PreventionDelayed Cerebral Ischemia PreventionGlasgow Coma Scale AssessmentPostmortem Examination FindingsSafety Profile CharacterizationSubarachnoid Hemorrhage Pharmacotherapy
OBJECT: Delayed cerebral ischemia remains an important cause of death and disability in patients who have suffered subarachnoid hemorrhage (SAH). Endothelin (ET) has a potent contractile effect on cerebral arteries and arterioles and has been implicated in vasospasm. The authors administered ET(A/B) receptor antagonist (TAK-044) to patients suffering from aneurysmal SAH. They then assessed whether this agent reduced the occurrence of delayed cerebral ischemic events and examined its safety profile in this group of patients. METHODS: Four hundred twenty patients who had suffered an SAH were recruited into a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II trial. The primary end point was whether a delayed ischemic event occurred within 3 months after the first dose of the study drug and the secondary end points included determining whether a delayed ischemic event occurred by 10 days after the first dose of the study drug, whether a new cerebral infarct was demonstrated on a computerized tomography scan or at postmortem examination by 3 months after administration of the initial dose, the patient's Glasgow Outcome Scale scores at 3 months after the initial dose, and adverse events. There was a lower incidence of delayed ischemic events at 3 months in the TAK-044-treated group: 29.5% compared with 36.6% in a group of patients receiving placebo. The estimated relative risk was 0.8 with a 95% confidence interval of 0.61 to 1.06. There were no significant differences in the secondary end points, including clinical outcomes in the placebo-treated and TAK-044-treated groups. CONCLUSIONS: The TAK-044 was well tolerated by patients who had suffered an SAH, even though hypotension and headache--side effects compatible with the drug's vasodilatory properties--occurred. It would be valuable to proceed to a fully powered phase III trial of an ET receptor antagonist in treating aneurysmal SAH.
11
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Graham M. Teasdale, Bryan Jennett · The Lancet · 1974 · 13.1K citations
ASSESSMENT OF OUTCOME AFTER SEVERE BRAIN DAMAGE A Practical Scale
B. Jennett · The Lancet · 1975 · 7.6K citations